Screening information for health professionals

The Australian Pancreatic High-RIsk ScrEening (APRISE) Study aims to assess the feasibility of implementing surveillance protocols among high-risk individuals with a familial and/or genetic predisposition to pancreatic cancer.

The APRISE study forms the Australian arm of the international collaboration with the Pancreatic Cancer Early Detection (PRECEDE) Consortium.

We are now accepting expressions of interest and referrals for the APRISE Study. Participation will involve:

• Baseline MRI/EUS and specialist review with follow-up appointments and assessments as clinically indicated.
• Annual questionnaires completed by the participant.

Individuals may be eligible for study if they fall into one of these high risk groups:

• Aged ≥ 18 and ≤ 90 years old

AND

• Without medical history of pancreatic cancer

AND

• Meet ANY of the following criteria:

1. Familial Pancreatic Cancer Group 1
• ≥2 relatives with pancreatic cancer, on same side of family, where the 2 affected are first degree related to each other
  AND
• ≥ 1 affected is first degree related to participant
  AND
• ≥50 years of age, or 10 years younger than earliest pancreatic cancer in family at time of diagnosis.

---

2. Familial Pancreatic Cancer Group 2
• ≥2 affected first degree relatives with pancreatic cancer
  AND
• ≥50 years of age, or 10 years younger than earliest pancreatic cancer in family.

---

3. Pathogenic Variants
• BRCA1, BRCA2, PALB2, ATM, MLH1, MSH2, MSH6, PMS2, or EPCAM pathogenic or likely pathogenic variant
  AND
• 1 first or second degree relative with pancreatic cancer
  AND
• ≥50 years of age, or 10 years younger than earliest pancreatic cancer in family.

---

4. Familial Atypical Multiple Mole Melanoma Syndrome (FAMMM)
• Familial Atypical Multiple Mole Melanoma (FAMMM) with pathogenic or likely pathogenic CDKN2A variant
  AND
• ≥40 years of age.

---

5. Peutz-Jeghers Syndrome
• Peutz-Jeghers syndrome with STK11 pathogenic or likely pathogenic variant
  AND
• ≥35 years of age.

---

6. Hereditary Pancreatitis
• Hereditary pancreatitis with PRSS1 pathogenic or likely pathogenic variant
  AND
• history of pancreatitis
  AND
• ≥40 years of age, or 20 years after onset of pancreatitis (whichever is earlier).

This study is proudly funded by Epworth HealthCare, PanKind – The Australian Pancreatic Cancer Foundation, the Viridian Foundation, and the Victorian Government through the Victorian Cancer Agency.